Shamburg News · 8-K filed Oct 22, 2026, 7:33 PM EDT

Retension Pharmaceuticals appoints Robert Wong as Vice President, Chief Accounting Officer

RTSN · Retension Pharmaceuticals, Inc.

  • Leadership change
  • Materiality: medium

On October 21, 2026, the Board of Directors of Retension Pharmaceuticals, Inc. appointed Robert Wong as Vice President, Chief Accounting Officer, effective November 2, 2026. Under an offer letter filed as Exhibit 10.1, Mr. Wong will receive an annual base salary of $360,000, a discretionary bonus target of 30% of base salary, a $20,000 sign-on bonus subject to employment through March 31, 2027, and an option to purchase 25,000 shares of common stock.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 9.01, accession 0001213900-26-111794.

Written from the filing by Shamburg Markets. Figures are as reported by the company.